首页 | 本学科首页   官方微博 | 高级检索  
   检索      

重组可溶性核因子κB受体活化因子体外抑制甲状旁腺激素诱导的破骨细胞生成
作者姓名:Wang BL  Liang H  Zheng F  Li XX  Liu YB  Dai CL
作者单位:1. 天津医科大学,内分泌研究所,天津,300070
2. 天津医科大学,基础医学院,天津,300070
3. 天津医科大学,总医院内分泌科,天津,300052
摘    要:新近发现的核因子κB受体活化因子配基(receptor activator of nuclear factor-κB ligand,RANKL),核因子κB受体活化因子(receptor activator ofnuclear factor-κB,RANK)/护骨素(osteoprotegerin,OPG)细胞因子系统提高了对破骨细胞生物学和骨稳态分子水平的认识。RANKL与RANK之间的相互作用决定了破骨细胞的分化。本研究通过体外实验评价可溶性RANK (soluble RANK,sRANK)是否可作为RANKL的拈抗剂下调破骨细胞生成和骨吸收陷窝的形成。构建sRANK的原核表达载体,转化入大肠杆菌表达菌株Origami B(DE3),成功表达了重组蛋白,亲和层析进行纯化。重组sRANK以剂量依赖方式抑制由甲状旁腺激素(parathyroid hormone,PTH)诱导的破骨细胞生成和骨吸收陷窝形成。RT-PCR实验证实,sRANK可显著抑制PTH刺激的小鼠骨髓细胞碳酸苷酶Ⅱ和抗酒石酸酸性磷酸酶mRNA的表达。结果表明,sRANK具有抗骨吸收功能,可能成为一种治疗以骨吸收加强为特征的骨疾病的新方法。

关 键 词:核因子κB受体活化因子  破骨细胞  体外  receptor  activator  of  nuclear  factor-κB
收稿时间:2006-10-10
修稿时间:2006-12-30

Recombinant soluble receptor activator of nuclear factor-kappaB inhibits parathyroid hormone-induced osteoclastogenesis in vitro
Wang BL,Liang H,Zheng F,Li XX,Liu YB,Dai CL.Recombinant soluble receptor activator of nuclear factor-kappaB inhibits parathyroid hormone-induced osteoclastogenesis in vitro[J].Acta Physiologica Sinica,2007,59(2):169-174.
Authors:Wang Bao-Li  Liang Hui  Zheng Fang  Li Xiao-Xia  Liu Yu-Bing  Dai Chen-Lin
Institution:Institute of Endocrinology; College of Basic Sciences, Tianjin Medical University, Tianjin 300070, China; Division of Endocrinology, Tianjin Medical University General Hospital, Tianjin 300052, China. E-mail: bliwang72@yahoo.com.cn.
Abstract:The recent identification of receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) cytokine system has led to a new molecular perspective on osteoclast biology and bone homeostasis. Specifically, the interaction between RANKL and RANK is responsible for osteoclast differentiation. In the present study, we evaluated whether soluble RANK (sRANK) could act as an antagonist of RANKL and down-regulate osteoclastogenesis and bone resorption in vitro. The prokaryotic expression vector coding for sRANK was constructed. Then the construct was introduced into E. coli Origami B (DE3) competent cells and recombinant sRANK was successfully produced and purified through affinity chromatography. sRANK reduced osteoclast-like cell (OLC) formation and resorption pit formation induced by parathyroid hormone (PTH) in a dose-dependent manner. In addition, sRANK significantly inhibited PTH-induced mRNA expression of carbonic anhydrase II and tartrate-resistant acid phosphatase in murine bone marrow cells as confirmed by using semi-quantitative RT-PCR. The down-regulation was highly correlated with the effect of sRANK on OLC formation from marrow cells. These data demonstrate the anti-resorptive effects of sRANK in vitro and highlight the potential of sRANK as a novel therapeutic approach to bone disorders characterized by enhanced bone resorption.
Keywords:osteoclasts  in vitro
本文献已被 CNKI 维普 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号